COL5A1 (Collagen Type V Alpha 1 Chain)

This study establishes MRPX as a robust biomarker for prognostic stratification and therapeutic guidance in PCa, offering new insights into biomechanical regulation of tumor progression and providing a potential avenue for precision oncology.

The characteristics of circCOL5A1 were verified by RNase R and actinomycin D experiments, and its subcellular localization was analyzed by PARIS kit...CircCOL5A1 promoted cell proliferation, migration, invasion, EMT and glycolysis by cytoplasmic adsorption of miR-3940-3p and up-regulation of KPNA2 in RCC. CircCOL5A1 is anticipated to be a promising molecular target for diagnosing and treating RCC.

COL5A1 expression is associated with tumor stage, with more pronounced expression in advanced-stage tumors.ConclusionCOL5A1 represented a novel potential prognostic indicator and therapeutic target in an HNC database sample, as its expression is closely linked to tumor progression, immune cell infiltration, and adverse clinical outcomes. These findings, primarily derived from squamous cell carcinoma-dominated cohorts, warrant further functional validation.

While 2D monolayers enriched TNF/NF-κB pathways, 3D cultures preferentially activated T cell-related, chemotactic, and JAK-STAT pathways, highlighting the critical influence of spatial context on innate and adaptive immune activation. These results establish the 3D GelMA-based GBM model as a robust preclinical platform and underscore ZIKV's potential as a multifaceted oncolytic virotherapy capable of both direct tumor lysis and immune modulation.

Collectively, BTI in meningioma is a metastatic and immunosuppressive zone. We have discovered potential biomarkers that help detect early metastasis and recurrence of meningioma.

ALKBH5 drives NNK-induced lung cancer via m6A demethylation of COL5A1, promoting tumor progression. Targeting the ALKBH5-COL5A1 axis may offer therapeutic strategies against tobacco-related cancers.

As a proof-of-concept, we showed that radiation-affected ECM genes are independent prognostic and predictive markers of radiotherapy benefit in MIBC. Future studies should validate these radiation-induced ECM changes in clinical samples, and explore the role of FLG in radioresistance.

Combined with protein profiling data, we speculate that SNHG11 may be involved in osteosarcoma progression by binding to SERPINB12 and regulating transcription. In conclusion, lncRNA SNHG11 plays a critical role in osteosarcoma development by regulating cellular information carriers at the DNA, RNA, and protein levels.

We developed an HLRGs-based prognostic model that predicts overall survival and guides treatment strategies, contributing to precision therapy in PC.

The discovery of the SPP1-CD44 ligand-receptor axis not only elucidates a novel inflammatory signaling pathway driving tumor progression, but also provides a potential therapeutic target for disrupting cancer-stromal interactions. Importantly, these biomarkers lay the foundation for developing precision immunotherapies that target the inflammatory-immune axis in GC management.

Furthermore, we found that normal astrocytes can be induced by GBM cells to activate the AKT/mTOR signaling pathway, migrate to the peritumoral region, and upregulate CAF-associated proteins (SERPINH1/COL5A1). These results suggest that astrocytes may serve as a potential source of CAF precursor cells within the GBM tumor microenvironment.

High correlation among these genes was confirmed in the protein-protein interaction network. This study identifies potential small-molecule drugs targeting stemness in CRC and highlights the prognostic value of the 10 key genes, offering insights into therapeutic targets for CRC treatment.